OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Multiple sclerosis: time for early treatment with high-efficacy drugs
Krzysztof Selmaj, Bruce Cree, Michael Barnett, et al.
Journal of Neurology (2023) Vol. 271, Iss. 1, pp. 105-115
Open Access | Times Cited: 27
Krzysztof Selmaj, Bruce Cree, Michael Barnett, et al.
Journal of Neurology (2023) Vol. 271, Iss. 1, pp. 105-115
Open Access | Times Cited: 27
Showing 1-25 of 27 citing articles:
An update on the role of magnetic resonance imaging in predicting and monitoring multiple sclerosis progression
Piriyankan Ananthavarathan, Nitin Sahi, Declan Chard
Expert Review of Neurotherapeutics (2024) Vol. 24, Iss. 2, pp. 201-216
Open Access | Times Cited: 11
Piriyankan Ananthavarathan, Nitin Sahi, Declan Chard
Expert Review of Neurotherapeutics (2024) Vol. 24, Iss. 2, pp. 201-216
Open Access | Times Cited: 11
Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review
Óscar Fernández, Per Soelberg Sørensen, Gıancarlo Comı, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
Óscar Fernández, Per Soelberg Sørensen, Gıancarlo Comı, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
Shifting from the treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis – real-world evidence from Germany
Steffeni Papukchieva, Ann-Sophie Stratil, Maria Kahn, et al.
Therapeutic Advances in Neurological Disorders (2024) Vol. 17
Open Access | Times Cited: 5
Steffeni Papukchieva, Ann-Sophie Stratil, Maria Kahn, et al.
Therapeutic Advances in Neurological Disorders (2024) Vol. 17
Open Access | Times Cited: 5
Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management
Celia Oreja‐Guevara, Sergio Martínez‐Yélamos, Sara Eichau, et al.
Therapeutic Advances in Neurological Disorders (2024) Vol. 17
Open Access | Times Cited: 4
Celia Oreja‐Guevara, Sergio Martínez‐Yélamos, Sara Eichau, et al.
Therapeutic Advances in Neurological Disorders (2024) Vol. 17
Open Access | Times Cited: 4
Cost–consequence analysis of early vs. delayed natalizumab use in highly active relapsing–remitting multiple sclerosis: a simulation study
Hernán Inojosa, Dirk Schriefer, Nils-Henning Neß, et al.
Journal of Neurology (2025) Vol. 272, Iss. 2
Open Access
Hernán Inojosa, Dirk Schriefer, Nils-Henning Neß, et al.
Journal of Neurology (2025) Vol. 272, Iss. 2
Open Access
Impact of oral Cladribine on paramagnetic rim lesions of Multiple Sclerosis patients
Mariano Marrodán, Paulina Yáñez, Ismael Luis Calandri, et al.
Multiple Sclerosis and Related Disorders (2025) Vol. 96, pp. 106339-106339
Closed Access
Mariano Marrodán, Paulina Yáñez, Ismael Luis Calandri, et al.
Multiple Sclerosis and Related Disorders (2025) Vol. 96, pp. 106339-106339
Closed Access
The Connection Between Oxidative Stress, Mitochondrial Dysfunction, Iron Metabolism and Microglia in Multiple Sclerosis: A Narrative Review
Simonida Delic, Svetlana Miletić Drakulić, Miloš Stepović, et al.
NeuroSci (2025) Vol. 6, Iss. 1, pp. 23-23
Open Access
Simonida Delic, Svetlana Miletić Drakulić, Miloš Stepović, et al.
NeuroSci (2025) Vol. 6, Iss. 1, pp. 23-23
Open Access
Long-Term Management and Therapeutic Sequencing for Patients with Relapsing Multiple Sclerosis in France: A Vignette Study
Patrick Vermersch, Xavier Moisset, Baptiste Roux, et al.
Neurology and Therapy (2025)
Open Access
Patrick Vermersch, Xavier Moisset, Baptiste Roux, et al.
Neurology and Therapy (2025)
Open Access
Monitoring multiple sclerosis: digital and fluid phase biomarkers
Kayla Ward, Stephen Reddel, Letizia Leocani, et al.
Current Opinion in Neurology (2025)
Closed Access
Kayla Ward, Stephen Reddel, Letizia Leocani, et al.
Current Opinion in Neurology (2025)
Closed Access
Update on novel multiple sclerosis treatments: from dismal defeat to scintillating success
Bruce Cree, Hans‐Peter Hartung
Current Opinion in Neurology (2025)
Closed Access
Bruce Cree, Hans‐Peter Hartung
Current Opinion in Neurology (2025)
Closed Access
Choosing initial MS therapy; personal, disease, and medication factors
Bruce A. Cohen
Neurotherapeutics (2025), pp. e00582-e00582
Open Access
Bruce A. Cohen
Neurotherapeutics (2025), pp. e00582-e00582
Open Access
Shifts in treatment initiation patterns among newly diagnosed multiple sclerosis patients in Germany: a claims data analysis from 2017 to 2022
Ann-Sophie Stratil, Steffeni Papukchieva, Natalie Joschko, et al.
Therapeutic Advances in Neurological Disorders (2025) Vol. 18
Open Access
Ann-Sophie Stratil, Steffeni Papukchieva, Natalie Joschko, et al.
Therapeutic Advances in Neurological Disorders (2025) Vol. 18
Open Access
Brain health – time matters: multiple sclerosis, neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and related conditions. 2024 report
Helmut Butzkueven, Gavin Giovannoni, Sofia Arkelsten, et al.
Multiple Sclerosis and Related Disorders (2025), pp. 106456-106456
Closed Access
Helmut Butzkueven, Gavin Giovannoni, Sofia Arkelsten, et al.
Multiple Sclerosis and Related Disorders (2025), pp. 106456-106456
Closed Access
MS treatment de-escalation: review and commentary
Krzysztof Selmaj, Hans‐Peter Hartung, Marcin P. Mycko, et al.
Journal of Neurology (2024) Vol. 271, Iss. 10, pp. 6426-6438
Open Access | Times Cited: 3
Krzysztof Selmaj, Hans‐Peter Hartung, Marcin P. Mycko, et al.
Journal of Neurology (2024) Vol. 271, Iss. 10, pp. 6426-6438
Open Access | Times Cited: 3
Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects
Piotr Olejnik, Zuzanna Roszkowska, Sylwia Adamus, et al.
Pharmacological Reports (2024) Vol. 76, Iss. 5, pp. 926-943
Open Access | Times Cited: 2
Piotr Olejnik, Zuzanna Roszkowska, Sylwia Adamus, et al.
Pharmacological Reports (2024) Vol. 76, Iss. 5, pp. 926-943
Open Access | Times Cited: 2
MiRNA-based therapeutic potential in multiple sclerosis
Ana Zabalza, Agustín Pappolla, Manuel Comabella, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Ana Zabalza, Agustín Pappolla, Manuel Comabella, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting
Simona Malucchi, Cecilia Irene Bava, Paola Valentino, et al.
Journal of Neurology (2024)
Closed Access | Times Cited: 2
Simona Malucchi, Cecilia Irene Bava, Paola Valentino, et al.
Journal of Neurology (2024)
Closed Access | Times Cited: 2
Improving the classification of multiple sclerosis and cerebral small vessel disease with interpretable transfer attention neural network
Wangshu Xu, Zhiwei Rong, Wenping Ma, et al.
Computers in Biology and Medicine (2024) Vol. 176, pp. 108530-108530
Closed Access | Times Cited: 1
Wangshu Xu, Zhiwei Rong, Wenping Ma, et al.
Computers in Biology and Medicine (2024) Vol. 176, pp. 108530-108530
Closed Access | Times Cited: 1
Change from platform to high efficacy disease-modifying treatment for multiple sclerosis despite NEDA
Yavor Yalachkov, Katja Akgün, Tjalf Ziemssen
Neuroimmunology Reports (2024) Vol. 5, pp. 100211-100211
Open Access
Yavor Yalachkov, Katja Akgün, Tjalf Ziemssen
Neuroimmunology Reports (2024) Vol. 5, pp. 100211-100211
Open Access
Impact of Ocrelizumab on Disease Progression, Memory Improvement, and Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal MRI and Clinical Criteria Analysis
Amanda Claudia Schuldesz, Ram Kiran Maganti, Raluca Tudor, et al.
Diseases (2024) Vol. 12, Iss. 6, pp. 127-127
Open Access
Amanda Claudia Schuldesz, Ram Kiran Maganti, Raluca Tudor, et al.
Diseases (2024) Vol. 12, Iss. 6, pp. 127-127
Open Access
Rituximab in secondary progressive multiple sclerosis: a meta‐analysis
Pasin Intarakhao, Taksaporn Laipasu, Jiraporn Jitprapaikulsan, et al.
Annals of Clinical and Translational Neurology (2024) Vol. 11, Iss. 10, pp. 2707-2718
Open Access
Pasin Intarakhao, Taksaporn Laipasu, Jiraporn Jitprapaikulsan, et al.
Annals of Clinical and Translational Neurology (2024) Vol. 11, Iss. 10, pp. 2707-2718
Open Access
Investigating When Patients With Multiple Sclerosis Should Switch From a Low- or Moderate-Efficacy Therapy to a High-Efficacy Treatment
Dennis Bourdette
Neurology (2024) Vol. 103, Iss. 6
Closed Access
Dennis Bourdette
Neurology (2024) Vol. 103, Iss. 6
Closed Access
Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First Generation Therapy to Elucidation of Immunomodulation and Repair
Rina Aharoni, Ron Milo, Ruth Arnon
Pharmacological Reviews (2024) Vol. 76, Iss. 6, pp. 1133-1158
Closed Access
Rina Aharoni, Ron Milo, Ruth Arnon
Pharmacological Reviews (2024) Vol. 76, Iss. 6, pp. 1133-1158
Closed Access
Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis
Enríque Alvarez, Lawrence Steinman, Edward Fox, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access
Enríque Alvarez, Lawrence Steinman, Edward Fox, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access
Holding your nerve in academia whilst managing multiple sclerosis
Aisha N. Bismillah, Stephen D. P. Fielden
Nature Reviews Chemistry (2024) Vol. 8, Iss. 11, pp. 793-794
Closed Access
Aisha N. Bismillah, Stephen D. P. Fielden
Nature Reviews Chemistry (2024) Vol. 8, Iss. 11, pp. 793-794
Closed Access
